Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 11/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | TSPO | P30536 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6416112 | 0.94 | PTPN1 (0.39) | CXCR2CXCR4TSPOALDH1A1MAPT | |
| SCHEMBL6418240 | 0.86 | GRM6 (0.40) | CXCR2CXCR4ALDH1A1MAPTLMNA | |
| SCHEMBL6849591 | 0.74 | ADORA1 (0.43) | ALDH1A1MAPTLMNA | |
| SCHEMBL6432093 | 0.70 | PTPN2 (0.34) | ALDH1A1MAPTPTPN2PTPN1KDM4E | |
| SCHEMBL7529881 | 0.68 | NT5E (0.39) | CXCR2CXCR4ALDH1A1MAPTNT5E | |
| SCHEMBL6416126 | 0.68 | PTPN1 (0.38) | CXCR2CXCR4PTPN2PTPN1 | |
| SCHEMBL6415638 | 0.64 | PTPN1 (0.45) | CXCR2PTPN2PTPN1 | |
| SCHEMBL6315579 | 0.62 | CXCR2 (0.44) | CXCR2CXCR4TSPOALDH1A1MAPT | |
| SCHEMBL6314950 | 0.62 | CXCR2 (0.46) | CXCR2CXCR4TSPOALDH1A1MAPT | |
| SCHEMBL5838158 | 0.62 | CXCR2 (0.54) | CXCR2CXCR4TSPOALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1404682-B1 | METHOD OF INHIBITING PTP 1B AND/OR T-CELL PTP AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | NOVO NORDISK AS (DK) | 2005-09-14 | — | — | EP | disclosed |
| US-20030064979-A1 | Method of inhibiting PTP 1B and /or T-cell PTP and/or other PTPases with an Asp residue at position 48 | NOVO NORDISK A/S (DK) | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064979-A1 | Method of inhibiting PTP 1B and /or T-cell PTP and/or other PTPases with an Asp residue at position 48 | PTPRO, PTPRF, PTPA | CXCR2 1476/4885CXCR4 2017/4885TSPO 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.